Gregory M. Weinhoff Sells 12,198 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 12,198 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total value of $148,449.66. Following the transaction, the insider now owns 241,171 shares in the company, valued at $2,935,051.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Centessa Pharmaceuticals Stock Up 5.3 %

Shares of CNTA opened at $12.85 on Friday. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36. The company has a 50-day moving average price of $10.15 and a two-hundred day moving average price of $10.05. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -9.05 and a beta of 1.40. Centessa Pharmaceuticals plc has a 12 month low of $5.15 and a 12 month high of $13.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Equities analysts predict that Centessa Pharmaceuticals plc will post -1.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jump Financial LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $114,000. Trexquant Investment LP bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $114,000. Franklin Resources Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 34.1% in the 4th quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock worth $8,882,000 after acquiring an additional 283,469 shares in the last quarter. Platinum Investment Management Ltd. grew its position in Centessa Pharmaceuticals by 12.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock worth $3,033,000 after acquiring an additional 43,539 shares during the last quarter. Finally, Octagon Capital Advisors LP increased its holdings in Centessa Pharmaceuticals by 333.2% during the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock valued at $16,398,000 after purchasing an additional 1,584,500 shares in the last quarter. 82.01% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CNTA. Morgan Stanley lifted their price objective on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Friday, June 21st. Oppenheimer reiterated an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.